Nacimbio supplied more than 1 million doses of TBE vaccine

| By | Microgen, Nacimbio, Rostec, Vaccine Production

In January – May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

“Rostec is actively expanding the range and output of Russian-made drugs for prevention of many diseases. Over several years, we were able to substantially reduce the dependence on foreign medicines. Investments in the development of new vaccines will allow to completely substitute the imported drugs by their Russian analogs in the future. The products for prevention of tick-borne encephalitis cost 1.5 – 2 less than their foreign analogs, which creates the conditions for exports,” said Oleg Yevtushenko, Executive Director of Rostec.

Such vaccines, as EnceVir and EnceVir Neo (for children), are concentrated purified sterile suspensions of inactivated tick-borne encephalitis virus, which enable human body to produce special antibodies that can generate immunity to the disease.

 “These drugs are first Russian-made tick-borne encephalitis vaccines that confirmed their high quality at the gene level based on the international recommendations of the World Health Organization. They can not only reduce the incidence, but also minimize the cases of severe complications, which is no less important,” said Kirill Gaidash, General Director of NPO Microgen. “Currently, the deliveries have been completed in full. Anyone can get preventive vaccination, including a free one, in the endemic regions of Russia.”

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.